Onco Preventer

Category: Uncategorized

  • Experts warn against unsupervised vitamin use and dietary trends in oncology – News

    In the ever-evolving world of health and wellness, it is tempting to latch onto popular diet trends or vitamin supplements with the hope of preventing diseases or improving treatment outcomes. However, a comprehensive new study coordinated by Dr. Salvatore Cortellino and Professor Antonio Giordano offers a sobering assessment of the promises often made by mass media and the booming wellness industry when it comes to cancer prevention and therapy. Published in the reputable journal Expert Review of Anticancer Therapy, this review brings clarity to a complex topic: the actual impact of vitamin supplements and popular diets on cancer patients. The study was bolstered by the insightful contributions of Teresa Esposito, MD, and Francesca Pentimalli, PhD, whose expertise in clinical dietetics and medicine helped shape the nuanced conclusions.

    One of the core revelations of the study is the recognition that while cancer patients frequently exhibit vitamin deficiencies—which may indeed increase cancer risk—pharmaceutical-grade multivitamins have yet to prove a clear clinical benefit when used in isolation. The research pivots away from the notion that popping vitamins can be a magic bullet against cancer. Instead, it underscores the proven importance of balanced nutrition, with particular emphasis on the Mediterranean diet. Rich in fruits, vegetables, whole grains, olive oil, and lean proteins, this dietary pattern provides an ideal blueprint for maintaining adequate micronutrient levels naturally. This is a diet long celebrated for its heart-healthy benefits, and now it receives further validation as an ally in cancer prevention.

    However, the study also sounds a cautionary note about the perils of hypervitaminosis—a condition resulting from an excess intake of vitamins without medical oversight. Such an imbalance, especially in individuals with cancer, could paradoxically promote tumor growth rather than inhibit it. This finding dispels the myth that “more is always better” when it comes to vitamin intake. Likewise, the research critically examines popular dietary regimens like the ketogenic diet, intermittent fasting, and even strict veganism. While these diets show promise in preclinical models, their effectiveness in actual human cancer therapy remains unproven. Moreover, the study raises concerns that these restrictive diets might exacerbate cancer-related cachexia, a wasting syndrome, or lead to malnutrition, particularly in vulnerable populations such as the elderly or frail patients.

    Professor Antonio Giordano, President of the Sbarro Health Research Organization, emphasizes the risks of blindly following dietary fads without medical guidance. "Our findings suggest that following dietary fashions without clinical guidance can be not only ineffective but potentially harmful for cancer patients. There is no substitute for evidence-based medicine and a personalized approach to nutrition," he cautions. This resonates deeply in a time when social media platforms amplify anecdotal success stories while sidelining clinical evidence. The authors advocate strongly for medical consultation before making any significant changes to diet or supplement regimens, especially in the presence of cancer risk or active disease. Qualified healthcare professionals, such as physicians and clinical dietitians, should be involved in these critical decisions to ensure patient safety and optimum therapeutic outcomes.

    The study concludes with a reaffirmation of timeless health principles: preserving physiological balance through adequate caloric intake, a varied and wholesome diet, and regular physical activity calibrated to individual needs. These foundational tenets—rooted in the European Code Against Cancer and the Mediterranean lifestyle—remain the most reliable pillars supporting cancer prevention and general wellbeing. These guidelines champion an approach that embraces moderation and personalization over quick fixes or extreme dietary experiments. At a time when the wellness industry is fraught with conflicting advice and unsubstantiated claims, this research serves as a clarion call to prioritize science-backed strategies and professional guidance when navigating nutrition in the context of cancer.

    #CancerPrevention #MediterraneanDiet #VitaminSupplements #HealthyEating #OncologyNutrition #EvidenceBasedHealth #WellnessTruths

    Source

  • Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Predictive Oncology, a pioneering science-driven company headquartered in Pittsburgh, continues to carve a notable niche in the realm of oncologic drug discovery by intertwining advanced artificial intelligence (AI), machine learning (ML), and a vast biorepository of tumor samples. Their first-quarter financial report for 2025 reveals a story of strategic evolution, focused innovation, and hopeful progress within the complex world of cancer drug development and personalized treatment solutions. Despite recording a loss of approximately $2.3 million on revenues totaling just over $110,000, the company’s operational highlights unveil exciting advancements that could reshape oncology drug pipelines.

    One of the standout breakthroughs from Predictive Oncology’s recent efforts is their innovative approach to repurposing abandoned or discontinued pharmaceutical compounds. By mining publicly available datasets on these “forgotten” drugs, the company established a promising registry aimed at finding new therapeutic indications, especially for cancer types like colon and breast tumors. This strategy is both cost-efficient and potentially groundbreaking, enabling drug developers to avoid the costly and time-intensive processes of designing new molecules from scratch. Among the compounds spotlighted are Afuresertib, Alisertib, and Entinosta, showing particular promise against breast and colon tumor indications. The repurposing paradigm not only accelerates drug development but also significantly curbs research and development expenditure—an ever-pressing concern for both biotech startups and pharmaceutical giants.

    In addition to drug repurposing, Predictive Oncology’s flagship product, the ChemoFx® live cell drug response assay, is gaining traction on an international scale with its planned European launch. Designed to quantify an individual cancer patient’s tumor response to a variety of chemotherapeutic drugs, this assay exemplifies the company’s commitment to personalized oncology. Initially targeting ovarian and other gynecological cancers, ChemoFx® aims to extend its diagnostic reach to other major tumor types, promising a tailored approach to cancer treatment. Personalized medicine, especially in oncology, remains one of the most dynamic frontiers in healthcare, moving away from one-size-fits-all therapies to treatments curated precisely for a patient’s unique tumor biology. Predictive Oncology’s focus on empowered diagnostics aligns perfectly with this trend and represents a significant chapter in oncology care evolution.

    Moreover, the company’s strategic divestment from Skyline Medical Inc., sold to DeRoyal Industries, signals a sharper focus on their core AI-enabled platforms while simultaneously reducing operating expenses. This move reiterates the company’s commitment to leveraging cutting-edge data analytics rather than managing diverse medical product lines, aligning the business closer with its core competencies. Alongside this, a collaborative partnership with Switzerland’s Tecan Group Ltd. showcases Predictive Oncology’s efforts to enhance high-throughput drug screening with advanced 3D tumor spheroid imaging technology. These cellular models better replicate tumor microenvironments and drug responses than traditional 2D cultures, improving the predictive power of preclinical drug screening. Presenting positive collaborative research results at the 2025 Society for Laboratory Automation and Screening (SLAS) International Conference underscores the scientific vigor behind these initiatives.

    Financially, Predictive Oncology’s first-quarter results demonstrate incremental improvements worth noting. With cash reserves increasing significantly to above $3 million from under $700,000 at the end of 2024, the company has better liquidity to support its innovative pipeline initiatives. Though its net loss per share narrowed compared to the previous year, the overall reduction in operating expenses—especially in general administration and sales & marketing—suggests an efficient maneuvering of resources. These cost improvements stem from reduced headcount and lower reliance on external consultants, reflecting a leaner operational model. As the company navigates the challenging biotech landscape, the goal remains clear: to transition from experimental phases to sustained growth by leveraging AI/ML technology in oncology, exploring attractive partnerships, and bringing advanced diagnostics like ChemoFx® to broader markets.

    Predictive Oncology’s journey reflects the broader trend of integrating artificial intelligence with traditional biomedicine, paving the way toward smarter, faster, and more precise drug discovery and patient care. Their focus on drug repurposing, combined with personalized tumor profiling assays and sophisticated screening technologies, underscores a future where innovation and pragmatism join forces to tackle one of humanity’s toughest diseases: cancer. With promising compounds on the horizon and strategic realignments that bolster financial health, the company’s strides exemplify how science, technology, and business acumen can converge to fulfill the urgent global need for novel cancer therapies.

    #PredictiveOncology #CancerResearch #DrugRepurposing #PersonalizedMedicine #AIinHealthcare #OncologyInnovation #BiotechUpdates

    Source

  • Artificial Intelligence Enhances Early Detection of Skin Cancer

    In the ever-evolving world of medical technology, a breakthrough has been achieved that promises to revolutionize how we detect one of the most common yet potentially deadly cancers—skin cancer. Researchers have developed an advanced artificial intelligence (AI) algorithm capable of analyzing dermoscopic images with extraordinary precision. Dermoscopy involves taking detailed photographs of skin lesions using specialized equipment, and this AI system can sift through these images to identify malignant tumors with an astonishing 95% sensitivity rate. This means the AI correctly detects 95 out of every 100 cancerous cases, marking a significant leap in accuracy over many existing diagnostic methods. Considering that skin cancer remains a global health challenge, with millions diagnosed each year, early and precise identification is vital for improving treatment outcomes and saving lives.

    Traditionally, dermatologists have been the frontline detectives in identifying skin cancer, relying on their trained eyes and experience to evaluate suspicious lesions visually. While dermoscopy has enhanced their capabilities by providing a magnified look at skin features beneath the surface, diagnosis can still be subject to human limitations. Variability in clinician assessments and subtle differences in lesion appearance can sometimes result in delayed or missed diagnoses. This is where AI steps in as a game-changer. By applying deep learning—a subset of machine learning that mimics neural networks in the human brain—the algorithm can process complex visual data to detect minuscule patterns and textural clues that may escape even the most experienced dermatologists. The consistency and objectivity offered by AI eliminate much of the guesswork, leading to a more standardized and reliable detection method.

    What makes this new AI system particularly exciting is not just its high sensitivity, but its potential to democratize healthcare. Many regions worldwide, particularly rural or underserved areas, face shortages of specialist dermatologists. Patients in these locations often experience delayed diagnoses due to limited access to expert evaluation. Integrating the AI algorithm into routine skin screenings could provide front-line healthcare providers with a powerful diagnostic assistant, bridging the gap caused by geographical and resource constraints. Clinics without specialized equipment or expert personnel might leverage this technology through smartphone apps or portable dermatoscopes connected to AI software, making early skin cancer detection more accessible than ever before.

    It's important to stress, however, that AI in medical diagnostics is designed to complement and augment human expertise, not replace it. Experts emphasize that while the algorithm offers a robust second opinion, the nuanced decision-making and comprehensive patient evaluation require the trained judgment of dermatologists. AI tools can flag lesions that warrant further investigation or provide reassurance when appearances suggest benign conditions, but final diagnoses and treatment plans remain firmly in the hands of healthcare professionals. This partnership between man and machine ensures the highest quality of care, combining the empathy and contextual insight of humans with the analytical power of advanced algorithms.

    Looking ahead, the medical community recognizes the importance of ongoing research to refine this AI technology further, ensuring it performs reliably across diverse populations and a wide variety of skin lesion types. Longitudinal clinical trials and real-world deployment studies will help establish guidelines for its integration into everyday practice, evaluating factors such as long-term accuracy, patient safety, and cost-effectiveness. The rise of AI in dermatology is emblematic of a larger trend toward precision medicine—leveraging data-driven tools to tailor diagnosis and treatment to individual patient profiles. As skin cancer rates continue to climb globally, innovations like this AI algorithm not only offer hope for reducing mortality rates but also signal a future where early detection is more effective, efficient, and accessible to all.

    #SkinCancerDetection #ArtificialIntelligence #MedicalInnovation #DermatologyBreakthrough #EarlyDiagnosis #AIInHealthcare #CancerAwareness

    Source

  • New Study Shows Promise of Immunotherapy in Pediatric Leukemia

    A recent study has brought promising news to the field of pediatric oncology, revealing that immunotherapy treatments are highly effective in treating pediatric leukemia, particularly acute lymphoblastic leukemia (ALL). This breakthrough offers renewed hope for young patients and their families who face the challenges of this serious illness. Acute lymphoblastic leukemia, a type of cancer that affects the white blood cells, is the most common form of leukemia in children. Traditionally, the primary approach to treating ALL has been chemotherapy, which, although effective in many cases, carries the risk of significant long-term side effects. These can include damage to various organs, increased susceptibility to infections, and developmental issues that can affect a child’s quality of life long after treatment has ended. The recent study focused on evaluating the effectiveness of immunotherapy, a treatment modality that enhances the body’s own immune system to recognize and attack cancer cells. Unlike chemotherapy, which targets rapidly dividing cells indiscriminately, immunotherapy is designed to specifically target leukemia cells, potentially minimizing damage to healthy tissues. According to the study’s findings, children with ALL who received immunotherapy exhibited notably higher remission rates compared to their counterparts who were treated with conventional chemotherapy alone. This significant improvement suggests that immunotherapy is more effective at eradicating leukemia cells and preventing relapse. Researchers involved in the study are optimistic about the implications of these results. They believe that immunotherapy has the potential to become a standard treatment option for pediatric leukemia. By integrating immunotherapy into treatment protocols, it may be possible to reduce the reliance on chemotherapy, thereby lowering the risk of adverse side effects that can impact children’s health in the long term. The study also emphasizes the importance of continuing research and clinical trials to further understand the full scope of immunotherapy’s benefits and to optimize treatment regimens for pediatric patients. Researchers are currently exploring various types of immunotherapy, including CAR T-cell therapy, monoclonal antibodies, and checkpoint inhibitors, to determine the most effective approaches for different subtypes of pediatric leukemia. Parents of children diagnosed with ALL are encouraged to discuss immunotherapy options with their healthcare providers, as emerging evidence suggests that these treatments may improve outcomes and quality of life for their children. Additionally, medical professionals are advocating for increased access to immunotherapy and supportive care services to ensure that all patients can benefit from the advancements in leukemia treatment. This study marks a significant step forward in pediatric cancer care, highlighting the potential of immunotherapy to transform the treatment landscape for childhood leukemia. Continued advancements in this field hold promise not only for improving survival rates but also for enhancing the long-term health and well-being of young patients worldwide.

  • Patient-Centered Management of Dermatologic Toxicities in Oncology: Insights From Cynthia Ryan, PharmD, BCPS

    Skin-related side effects from cancer treatments can be more than just a cosmetic concern—they can significantly impact a patient’s wellbeing and adherence to therapy. In a detailed interview, Cynthia Ryan, PharmD, BCPS, a clinical oncology specialist at the University of Colorado Hospital Pharmacy, illuminated the important strides being made through the Association of Cancer Care Centers (ACCC)'s initiative focused on supportive care strategies for dermatologic toxicities. This pioneering project is dedicated to improving how healthcare providers, including pharmacists, recognize, prevent, and treat skin toxicities caused by various cancer drugs. By promoting interdisciplinary collaboration and offering practical tools, the ACCC aims to enhance patient quality of life and keep cancer therapies on track without interruptions caused by uncomfortable or disfiguring skin issues.

    Dermatologic toxicities present in various ways depending on the anti-cancer agent involved. For instance, immunotherapy commonly causes rashes and itching, which, while sometimes mild, can be distressing or lead to infections if untreated. Liposomal doxorubicin, capecitabine, and oral vascular endothelial growth factor (VEGF) inhibitors often trigger hand-foot syndrome (HFS), a condition characterized by redness, swelling, and pain on the palms and soles, making everyday activities challenging. Epidermal growth factor receptor (EGFR) inhibitors, along with trametinib, frequently cause acneiform rashes that resemble severe acne and mucositis—painful inflammation and ulceration of the mucous membranes. Moreover, alopecia or hair loss remains a widely recognized side effect across many anti-cancer therapies, adding to the emotional burden cancer patients carry. Understanding these agent-specific skin reactions helps clinicians personalize supportive care strategies to each patient’s treatment regimen.

    Accurate assessment of these dermatologic adverse events (AEs) is crucial and relies on established clinical tools. The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) offers a standardized way to grade the severity of skin toxicities, aiding in consistent communication among healthcare providers. Complementing this, quality of life (QOL) instruments like Skindex-16 allow clinicians to quantify how skin symptoms affect patients’ daily functioning and emotional health. This dual approach ensures that the physical and psychological impact of dermatologic toxicities is not underestimated. Pharmacists, often on the frontline of patient care, can play a pivotal role by utilizing these tools during routine assessments and by facilitating timely referrals to dermatology specialists. With modern electronic health records (EHRs), documenting detailed clinical notes and even photographs of skin reactions enables close monitoring of progression or improvement, which enhances individualized treatment plans.

    When it comes to managing these skin side effects, evidence-based strategies can provide significant relief and prevent complications. For example, preventing rash associated with EGFR inhibitors is effectively achieved using hydrocortisone 1% cream, sunscreen, and oral antibiotics such as doxycycline or minocycline during the initial six weeks of treatment. Should a rash develop, medium to high-potency steroid creams combined with continued doxycycline use remain the mainstay. For pruritus or itching, topical steroids and oral antihistamines are first-line, though gabapentinoids may be considered for refractory cases. Hand-foot syndrome prevention includes regular use of urea-containing emollients, while topical diclofenac creams have been shown to reduce the incidence linked to capecitabine. Rash and pruritus caused by immunotherapy also respond to steroids and antihistamines, with escalation to agents like aprepitant in stubborn cases. These nuanced treatment pathways underscore the vital role pharmacists have in educating patients on timely initiation and continuous adherence to these supportive measures.

    Beyond management, prevention and education stand out as key pillars in preserving patients’ quality of life and adherence to life-saving cancer therapies. Patients on EGFR inhibitors, for instance, benefit from counseling on gentle skin care habits—washing with tepid water, avoiding perfumed or antibacterial soaps, applying broad-spectrum sunscreen (SPF 30 or higher) regularly, and moisturizing twice daily—to maintain skin integrity. Those at risk for hand-foot syndrome should be advised to steer clear of activities that generate heat and friction on the hands and feet. Most importantly, patients and caregivers must be equipped with clear guidance on recognizing early dermatologic symptoms and understanding when to seek medical attention, especially for rare but serious conditions like Stevens-Johnson Syndrome or toxic epidermal necrolysis. This proactive approach not only improves patient comfort but also significantly supports ongoing cancer treatment adherence by preventing severe interruptions or dose modifications.

    Pharmacists, as accessible and knowledgeable healthcare professionals, are central to the successful implementation of these initiatives. They can conduct early and routine toxicity assessments, educate patients and caregivers, coordinate with dermatologists, and leverage patient-reported outcomes (PROs) and electronic health records to monitor side effect progression remotely. In fact, some advanced EHR systems enable patients to upload photos of skin changes, providing real-time information for clinicians to act swiftly. Furthermore, comprehensive educational programs offered by organizations such as the ACCC empower pharmacists to stay abreast of evolving best practices in the management of dermatologic toxicities. This continuous learning ensures that oncology pharmacists serve as vital advocates, mitigating dermatologic complications and fostering sustained adherence to cancer therapies—ultimately contributing to better patient outcomes and quality of life.

    #CancerCare
    #OncologyPharmacy
    #DermatologicToxicities
    #PatientSupport
    #PharmacistRole
    #SkinCareInCancer
    #ACCCInitiative

    Source

  • Andy Minn, MD, PhD, will rejoin Memorial Sloan Kettering Cancer Center as the Inaugural Chair of MSK’s new Immuno-Oncology Program

    Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Joan Massagué, PhD, and his residency in the Department of Radiation Oncology, both at MSK, in 2003 and 2005 respectively.

    “We are extremely fortunate to have a leader of Dr. Minn’s unparalleled caliber and global reputation at the helm of MSK’s Immuno-Oncology Program,” said Selwyn M. Vickers, MD, FACS, President and CEO of MSK. “He will help lead MSK toward a future of ongoing collaboration and discovery that will ignite our research, delivering unprecedented benefits to our patients as MSK continues to advance immuno-oncology, the world’s next frontier in cancer research.”

    Dr. Minn joins MSK from the University of Pennsylvania, where he has been Director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation; Professor in the Department of Radiation Oncology at the Perelman School of Medicine; a member of the Parker Institute for Cancer Immunotherapy; and an Investigator at the Abramson Family Cancer Research Institute.

    As a researcher, Dr. Minn has focused on understanding how long-term inflammation and the abnormal activation of antiviral pathways, such as interferon (IFN), and other inflammatory cascades impact cancer progression, treatment resistance, and immunotherapy response. He employs both experimental and translational strategies to drive discoveries from bench to bedside. His studies have led to several clinical trials.

    Dr. Minn’s recent efforts have focused on finding different strategies to restore productive IFN signaling in cancer by using CAR-T cells, targeting key signaling hubs, and blocking persistent and maladaptive IFN and inflammatory signaling in cancer and immune cells with JAK inhibitors. He and his lab colleagues are seeking to improve immunotherapy by discovering, understanding, and targeting chronic IFN and other inflammatory pathways that drive suppressive tumor-immune system states, leading to relapse and therapy resistance.

    With his extensive experience as a scientist, clinician, and researcher, Dr. Minn will bring a new, broad perspective to MSK’s recently established Immuno-Oncology Program. The program builds on MSK’s pioneering contributions in the development of immune checkpoint blockade therapy, chimeric antigen receptor (CAR-T) and other cellular therapies, and cancer vaccines. Under Dr. Minn’s leadership, the Immuno-Oncology Program will serve as a central hub for comprehensive immuno-oncology research, providing resources and collaboration opportunities to colleagues across MSK. The program’s focus will be on expanding our collective knowledge of the immune system and developing immunotherapies that are more effective, against more types of cancer, for a greater number of people, advancing MSK’s mission of ending cancer for life.

    Dr. Minn received his MD and PhD from the University of Chicago where he studied the structure, function, and regulation of programmed cell death genes with Craig Thompson, MD, former President and CEO of MSK and currently the Benno C. Schmidt Chair of Cancer Research. After completing his postdoc at MSK, Dr. Minn returned to the University of Chicago where he served as Assistant Professor in the Department of Radiation & Cellular Oncology and a member of the Ludwig Center for Metastasis Research before moving to the University of Pennsylvania.

  • Andy Minn, MD, PhD, will rejoin Memorial Sloan Kettering Cancer Center as the Inaugural Chair of MSK’s new Immuno-Oncology Program

    Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Joan Massagué, PhD, and his residency in the Department of Radiation Oncology, both at MSK, in 2003 and 2005 respectively.

    “We are extremely fortunate to have a leader of Dr. Minn’s unparalleled caliber and global reputation at the helm of MSK’s Immuno-Oncology Program,” said Selwyn M. Vickers, MD, FACS, President and CEO of MSK. “He will help lead MSK toward a future of ongoing collaboration and discovery that will ignite our research, delivering unprecedented benefits to our patients as MSK continues to advance immuno-oncology, the world’s next frontier in cancer research.”

    Dr. Minn joins MSK from the University of Pennsylvania, where he has been Director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation; Professor in the Department of Radiation Oncology at the Perelman School of Medicine; a member of the Parker Institute for Cancer Immunotherapy; and an Investigator at the Abramson Family Cancer Research Institute.

    As a researcher, Dr. Minn has focused on understanding how long-term inflammation and the abnormal activation of antiviral pathways, such as interferon (IFN), and other inflammatory cascades impact cancer progression, treatment resistance, and immunotherapy response. He employs both experimental and translational strategies to drive discoveries from bench to bedside. His studies have led to several clinical trials.

    Dr. Minn’s recent efforts have focused on finding different strategies to restore productive IFN signaling in cancer by using CAR-T cells, targeting key signaling hubs, and blocking persistent and maladaptive IFN and inflammatory signaling in cancer and immune cells with JAK inhibitors. He and his lab colleagues are seeking to improve immunotherapy by discovering, understanding, and targeting chronic IFN and other inflammatory pathways that drive suppressive tumor-immune system states, leading to relapse and therapy resistance.

    With his extensive experience as a scientist, clinician, and researcher, Dr. Minn will bring a new, broad perspective to MSK’s recently established Immuno-Oncology Program. The program builds on MSK’s pioneering contributions in the development of immune checkpoint blockade therapy, chimeric antigen receptor (CAR-T) and other cellular therapies, and cancer vaccines. Under Dr. Minn’s leadership, the Immuno-Oncology Program will serve as a central hub for comprehensive immuno-oncology research, providing resources and collaboration opportunities to colleagues across MSK. The program’s focus will be on expanding our collective knowledge of the immune system and developing immunotherapies that are more effective, against more types of cancer, for a greater number of people, advancing MSK’s mission of ending cancer for life.

    Dr. Minn received his MD and PhD from the University of Chicago where he studied the structure, function, and regulation of programmed cell death genes with Craig Thompson, MD, former President and CEO of MSK and currently the Benno C. Schmidt Chair of Cancer Research. After completing his postdoc at MSK, Dr. Minn returned to the University of Chicago where he served as Assistant Professor in the Department of Radiation & Cellular Oncology and a member of the Ludwig Center for Metastasis Research before moving to the University of Pennsylvania.

  • New Guidelines Recommend HPV Vaccination for All Adults

    The Centers for Disease Control and Prevention (CDC) has recently updated its vaccination guidelines to include a broad recommendation for Human Papillomavirus (HPV) vaccination among adults up to the age of 45. This important update comes as part of ongoing efforts to enhance public health measures aimed at preventing a range of cancers linked to HPV infection. Human papillomavirus is a common virus that can lead to several types of cancers, including cervical, anal, and oropharyngeal cancers. These cancers represent significant public health challenges due to their prevalence and potential severity. The CDC's expanded recommendation underscores the critical role vaccination plays in reducing the incidence of these diseases across a wider age group than previously advised. Historically, HPV vaccination was primarily targeted towards younger populations, with the intention of vaccinating individuals before they become sexually active and potentially exposed to the virus. This approach has proven effective in reducing HPV infections and subsequent cancer cases in vaccinated cohorts. However, recognizing that many adults remain susceptible to HPV infection and can still derive protective benefits from vaccination, the CDC has extended the recommendation. The new guidelines clarify that while vaccination is most effective when administered before any exposure to HPV, adults aged 27 to 45 can still benefit from receiving the vaccine. This expansion is particularly significant for adults who may not have been vaccinated during adolescence or those who have new or multiple sexual partners, increasing their risk of HPV exposure. Healthcare providers are now encouraged to engage in thorough discussions with their patients about the potential benefits and considerations of HPV vaccination based on individual risk factors and health status. This patient-centered approach will help identify those who stand to gain the most from vaccination within the extended age range. The CDC's updated recommendations are supported by recent studies demonstrating the vaccine's safety and effectiveness in older adults. Additionally, expanding vaccination efforts can contribute to reducing the overall burden of HPV-related diseases, improve public health outcomes, and potentially decrease healthcare costs associated with treating HPV-related cancers. Public health organizations and medical experts have welcomed the CDC's updated guidance as a critical step towards comprehensive cancer prevention strategies. Educational campaigns and healthcare provider training are anticipated to follow, ensuring that the broader population is informed about the benefits of HPV vaccination and encouraged to participate. Overall, the CDC’s broadened HPV vaccination guidelines signify an important advancement in preventive healthcare. Adults up to the age of 45 are now recognized as candidates for the vaccine, highlighting a proactive approach to reducing HPV-associated cancer risks and promoting long-term health benefits across a larger segment of the population.

  • Largest Genomic Study of Veterans with Metastatic Prostate Cancer Reveals Critical Insights for Precision Medicine | Newswise

    Newswise — TAMPA, Fla. (May 16, 2025) — In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care.

    The study, published in JAMA Network Open, analyzed data from more than 5,000 U.S. veterans with metastatic prostate cancer who underwent next-generation sequencing between 2019 and 2023. It found that while non-Hispanic Black veterans had higher rates of actionable immunotherapy targets, non-Hispanic white veterans had more frequent alterations in androgen receptor signaling and DNA repair pathways. Despite these biological differences, survival outcomes were comparable in the equal-access VA setting.

    “These results affirm that precision oncology can be a powerful tool for achieving equitable cancer care,” said Kosj Yamoah, M.D., Ph.D., senior author and chair of the Radiation Oncology Program at Moffitt. “By using genomic testing to guide therapy selection, we can match patients to treatments based on their tumor biology, not race.”

    Dr. Isla Garraway, M.D., Ph.D., co-senior author and director of research in the Urology Department at UCLA Health, emphasized the importance of the study’s implications, “This research reinforces that we must not let historical disparities define modern care. Instead, by prioritizing access to genomic tools, we can drive meaningful change in how prostate cancer is treated across all populations.”

    Their key findings include:

    Non-Hispanic Black veterans were significantly more likely to have genomic alterations associated with immunotherapy benefit, such as microsatellite instability.

    Non-Hispanic white veterans had higher rates of mutations in DNA repair genes and the androgen receptor axis, which may influence responsiveness to hormonal therapies.

    Tumor suppressor gene alterations were linked to worse survival in both groups.

    No biomarker was found that should be excluded from testing based on race.

    The study’s diverse cohort, consisting of 36% non-Hispanic Black veterans, represents a marked improvement in inclusion compared to previous genomic studies. Researchers emphasized the importance of continuing to broaden access to next-generation sequencing testing and ensuring that underrepresented groups are included in precision oncology research and clinical trials.

    “This study shows that when we remove barriers to care and apply precision medicine equitably, we can improve outcomes for all patients,” said Kara Maxwell, M.D., Ph.D., co-senior author and assistant professor of medicine at the University of Pennsylvania’s Perelman School of Medicine.

    The research was supported by the National Cancer Institute (P30-CA076292), the Prostate Cancer Foundation (PCF22CHAL02) and the VA National Precision Oncology Program.

    About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

    ###

  • The OncFive: Top Oncology Articles for the Week of 5/11

    Welcome to OncLive®’s OncFive!

    Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.

    Here’s what you may have missed this week:

    FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression

    The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a first-in-class antibody-drug conjugate (ADC), for adults with previously treated, locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) exhibiting high c-MET protein overexpression. Approval was supported by the phase 2 LUMINOSITY trial (NCT03539536), which demonstrated a 35% overall response rate (ORR) and a median duration of response (DOR) of 7.2 months in this patient population. Concurrently, the regulatory agency greenlit Roche’s VENTANA MET (SP44) RxDx Assay as a companion diagnostic to identify eligible patients via immunohistochemistry. Safety findings were consistent with known ADC toxicities, including peripheral neuropathy and fatigue. This decision marks a significant step forward for biomarker-driven lung cancer therapy, addressing a critical unmet need in patients with high c-MET expression.

    FDA Approves Retifanlimab for Advanced Anal Cancer

    The FDA has cleared retifanlimab-dlwr (Zynyz) paired with carboplatin and paclitaxel as a first-line treatment for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC), and as monotherapy for those with disease progression after platinum-based chemotherapy. These approvals are based on results from the phase 3 POD1UM-303/InterAACT2 trial (NCT04472429), which showed that the combination significantly improved progression-free survival and overall survival (OS) vs chemotherapy alone. Retifanlimab plus chemotherapy achieved a 56% ORR, with a median DOR of 14 months, and showed a manageable toxicity profile with no new safety signals. Data from the phase 2 POD1UM-202 trial (NCT03597295) also supported the monotherapy approval, showing a 14% ORR and disease control in nearly half of previously treated patients. This marks a major advancement for SCAC treatment, addressing a long-standing gap in options for this rare and often overlooked cancer.

    FDA Clears Belzutifan for Advanced Pheochromocytoma and Paraganglioma

    The FDA has greenlit belzutifan (Welireg) for adults and adolescents aged 12 and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. The decision is based on data from the phase 2 LITESPARK-015 trial (NCT04924075), where belzutifan achieved a 26% ORR and a median DOR of 20.4 months, with over half of responders maintaining benefit for at least a year. Notably, 32% of patients reduced their use of antihypertensive medications by at least 50% for 6 months or more, signaling a clinical benefit beyond tumor shrinkage. Belzutifan demonstrated a manageable safety profile, with anemia, fatigue, and musculoskeletal pain among the most common adverse effects. This marks the third FDA-approved indication for belzutifan, expanding its role as a targeted therapy across rare and difficult-to-treat tumors.

    Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting

    As excitement builds for the 2025 ASCO Annual Meeting, breast cancer experts are closely watching several high-impact studies that could reshape treatment paradigms. Among the most anticipated is the ASCENT-04 trial (NCT05382286), which may establish sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) as a new first-line option for PD-L1–positive metastatic triple-negative breast cancer. The SERENA-6 trial (NCT04964934) is also generating buzz for challenging conventional sequencing by using circulating tumor DNA to guide early intervention with camizestrant in hormone receptor–positive, HER2-negative disease. Experts are eager to see if DESTINY-Breast09 (NCT04784715) data will shift the first-line standard in HER2+ metastatic breast cancer by favoring trastuzumab deruxtecan-nxki (Enhertu)–based regimens. Sign up to access the full breast cancer preview.

    Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

    With the meeting approaching, lung cancer experts are also eagerly anticipating data from several high-stakes trials that are poised to reshape standards of care. Leading the conversation is the phase 3 DeLLphi-304 trial (NCT05740566), where tarlatamab-dlle (Imdelltra) has shown a significant OS benefit over chemotherapy in relapsed small cell lung cancer. The IMforte trial (NCT05091567) is also generating interest for its potential to establish lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) as a new maintenance regimen in extensive-stage disease. In the non–small cell setting, eyes are on CheckMate 816 (NCT02998528)’s OS update and promising HER2-targeted therapies like BAY 2927088. Additional excitement surrounds novel approaches in stage III disease, EGFR-resistant populations, and adaptive biomarker-driven strategies that signal a shift toward more personalized care. Sign up to access the resource.